HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Abe DeAnda, Jr Marc R. Moon Conrad M. Vial Masashi Komeda Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DeAnda, A. Articles by Miller, D. C. Search for Related Content PubMed PubMed Citation Articles by DeAnda, A., Jr Articles by Miller, D. C.

Ann Thorac Surg 1994;58:344-350
© 1994 The Society of Thoracic Surgeons

---

Articles

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

^a Department of Cardiovascular and Thoracic Surgery, Stanford University Schnol of Medicine, Stanford, California, USA
^b Department of Cardiovascular and Thoracic Surgery, Gilead Sciences, Foster City, California USA

^_* Address reprint requests to Dr Miller, Department of Cardiovascular and Thoracic Surgery, Palk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94305-5247.

Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamer's clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg · kg^–1 · min^–1 dose, the activated clotting time rose with aptamer infusion from 106 ± 12 seconds to 187 ± 8 seconds (± 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 ± 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography. The calculated plasma aptamer elimination half-life increased from 1.9 minutes during baseline conditions to 7.7 minutes during total bypass, suggesting that the pulmonary vasculature plays a role in aptamer clearance. Importantly, the coagulation profile returned to normal levels within 5 minutes of halting aptamer infusion. There was no difference in platelet or fibrinogen consumption versus those of heparin. Postoperative bleeding (chest tube output) was minimal (95 to 150 mL over a 2-hour period), and serum chemistry profiles were normal. These preliminary pilot data indicate that this thrombin aptamer is both safe and, using conventional measures of anticoagulation, effective as an anticoagulant in this short-term canine CPB model, and that its pharmacokinetics are predictable. Furthermore, the pulmonary circulation appears to play a major role in the clearance of the aptamer.

This article has been cited by other articles:

				S. M. Nimjee, S. Oney, Z. Volovyk, K. M. Bompiani, S. B. Long, M. Hoffman, and B. A. Sullenger Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin RNA, December 1, 2009; 15(12): 2105 - 2111. [Abstract] [Full Text] [PDF]

				Y. Kim, J. A. Phillips, H. Liu, H. Kang, and W. Tan Using photons to manipulate enzyme inhibition by an azobenzene-modified nucleic acid probe PNAS, April 21, 2009; 106(16): 6489 - 6494. [Abstract] [Full Text] [PDF]

				Y. Kim, Z. Cao, and W. Tan Molecular assembly for high-performance bivalent nucleic acid inhibitor PNAS, April 15, 2008; 105(15): 5664 - 5669. [Abstract] [Full Text] [PDF]

				K. Ikebukuro, Y. Okumura, K. Sumikura, and I. Karube A novel method of screening thrombin-inhibiting DNA aptamers using an evolution-mimicking algorithm Nucleic Acids Res., July 7, 2005; 33(12): e108 - e108. [Abstract] [Full Text] [PDF]

				F. Andreotti and R. C. Becker Atherothrombotic Disorders: New Insights From Hematology Circulation, April 12, 2005; 111(14): 1855 - 1863. [Full Text] [PDF]

				R. R. White, S. Shan, C. P. Rusconi, G. Shetty, M. W. Dewhirst, C. D. Kontos, and B. A. Sullenger Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 PNAS, April 29, 2003; 100(9): 5028 - 5033. [Abstract] [Full Text] [PDF]

				F. Follis and C. A. Schmidt Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis Ann. Thorac. Surg., December 1, 2000; 70(6): 2173 - 2181. [Abstract] [Full Text] [PDF]

				J. W. Frederiksen Cardiopulmonary bypass in humans: bypassing unfractionated heparin Ann. Thorac. Surg., October 1, 2000; 70(4): 1434 - 1443. [Abstract] [Full Text] [PDF]

				M. J. Wilhelm, C. Schmid, D. Kececioglu, T. Mollhoff, H. Ostermann, and H. H. Scheld Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Using Org 10172 Ann. Thorac. Surg., March 1, 1996; 61(3): 920 - 924. [Abstract] [Full Text]